secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277569
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Kyverna Therapeutics reports Q3 results, positive gMG interim data, $150M loan facility, SPS data early 2026
--------------------------------------------------------------------------------

- Kyverna reported Q3 2025 net loss of $36.8M ($0.85 per share), R&D expenses $30.5M, G&A $8.3M; cash $171.1M as of Sep 30, 2025.
- Positive interim Phase 2 data in generalized myasthenia gravis: all primary and secondary endpoints met, 100% of patients achieved sustained reductions in MG-ADL and QMG at 24 weeks.
- Topline data from registrational stiff person syndrome trial expected early 2026 (narrowed from 1H 2026); BLA submission anticipated in 1H 2026.
- Closed up to $150M loan facility with Oxford Finance, initial $25M drawn; cash runway extended into 2027.
- On track to file IND for KYV-102 (whole blood rapid manufacturing) in Q4 2025; Phase 3 gMG enrollment by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/0001193125-25-277569-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000119312525277569/kytx-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277569

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer